Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption

J. E. Herrero-González; C. Sitaru; E. Klinker; E. B. Bröckert; Detlef Zillikens

doi:10.1111/j.1365-2230.2005.01853.x

Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption

J. E. Herrero-González, C. Sitaru, E. Klinker, E. B. Bröckert, Detlef Zillikens^*

^*Corresponding author for this work

Department of Dermatology, Allergology and Venereology

University of Würzburg

25 Citations (Scopus)

Abstract

Bullous pemphigoid (BP) is an autoimmune blistering skin disease associated with circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. We report two cases of therapy-refractory BP adjuvantly treated by tryptophan immunoadsorption. In both patients, this treatment was associated with rapid clinical improvement and reduction in the required corticosteroid dosage. In addition, levels of circulating anti-BP180 autoantibodies decreased markedly. Antibodies that were eluted from the tryptophan matrix bound to BP180 and induced dermal-epidermal separation in cryosections of human skin. Our observations suggest that immunoadsorption may be a helpful adjuvant treatment in severe BP.

Original language	English
Journal	Clinical and Experimental Dermatology
Volume	30
Issue number	5
Pages (from-to)	519-522
Number of pages	4
ISSN	0307-6938
DOIs	https://doi.org/10.1111/j.1365-2230.2005.01853.x
Publication status	Published - 09.2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1111/j.1365-2230.2005.01853.x

Cite this

@article{61c2ee754e744c29b9266cf99cc4c1c5,

title = "Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption",

abstract = "Bullous pemphigoid (BP) is an autoimmune blistering skin disease associated with circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. We report two cases of therapy-refractory BP adjuvantly treated by tryptophan immunoadsorption. In both patients, this treatment was associated with rapid clinical improvement and reduction in the required corticosteroid dosage. In addition, levels of circulating anti-BP180 autoantibodies decreased markedly. Antibodies that were eluted from the tryptophan matrix bound to BP180 and induced dermal-epidermal separation in cryosections of human skin. Our observations suggest that immunoadsorption may be a helpful adjuvant treatment in severe BP.",

author = "Herrero-Gonz{\'a}lez, \{J. E.\} and C. Sitaru and E. Klinker and Br{\"o}ckert, \{E. B.\} and Detlef Zillikens",

year = "2005",

month = sep,

doi = "10.1111/j.1365-2230.2005.01853.x",

language = "English",

volume = "30",

pages = "519--522",

journal = "Clinical and Experimental Dermatology",

issn = "0307-6938",

publisher = "Oxford University Press",

number = "5",

}

TY - JOUR

T1 - Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption

AU - Herrero-González, J. E.

AU - Sitaru, C.

AU - Klinker, E.

AU - Bröckert, E. B.

AU - Zillikens, Detlef

PY - 2005/9

Y1 - 2005/9

N2 - Bullous pemphigoid (BP) is an autoimmune blistering skin disease associated with circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. We report two cases of therapy-refractory BP adjuvantly treated by tryptophan immunoadsorption. In both patients, this treatment was associated with rapid clinical improvement and reduction in the required corticosteroid dosage. In addition, levels of circulating anti-BP180 autoantibodies decreased markedly. Antibodies that were eluted from the tryptophan matrix bound to BP180 and induced dermal-epidermal separation in cryosections of human skin. Our observations suggest that immunoadsorption may be a helpful adjuvant treatment in severe BP.

AB - Bullous pemphigoid (BP) is an autoimmune blistering skin disease associated with circulating autoantibodies to the hemidesmosomal antigens BP180 and BP230. We report two cases of therapy-refractory BP adjuvantly treated by tryptophan immunoadsorption. In both patients, this treatment was associated with rapid clinical improvement and reduction in the required corticosteroid dosage. In addition, levels of circulating anti-BP180 autoantibodies decreased markedly. Antibodies that were eluted from the tryptophan matrix bound to BP180 and induced dermal-epidermal separation in cryosections of human skin. Our observations suggest that immunoadsorption may be a helpful adjuvant treatment in severe BP.

UR - https://www.scopus.com/pages/publications/23044438369

U2 - 10.1111/j.1365-2230.2005.01853.x

DO - 10.1111/j.1365-2230.2005.01853.x

M3 - Journal articles

C2 - 16045683

AN - SCOPUS:23044438369

SN - 0307-6938

VL - 30

SP - 519

EP - 522

JO - Clinical and Experimental Dermatology

JF - Clinical and Experimental Dermatology

IS - 5

ER -

Successful adjuvant treatment of severe bullous pemphigoid by tryptophan immunoadsorption

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this